Course Description
Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
Learning Objectives
Management of Attention-Deficit/Hyperactivity Disorder (ADHD): Considerations for Adults
- Evaluate adult patients for attention-deficit/hyperactivity disorder (ADHD) using screening tools and rating scales.
- Formulate treatment plans for adult patients with ADHD.
- Identify appropriate stimulant medication alternatives during a medication shortage.
- Examine how artificial intelligence programs can be used to enhance mental health care.
- Describe the limitations and ethical concerns associated with using artificial intelligence programs in the provision of mental health care.
- Assess infrastructure needs for integrating artificial intelligence into psychiatric clinical practice.
- Evaluate current literature that supports a diagnosis of benzodiazepine-induced neurological dysfunction (BIND).
- Identify risk factors and/or prevention strategies for development of BIND.
- Create a treatment plan for management of BIND.
- Identify microaggressions impacting vulnerable populations.
- Assess the impact of microaggressions on the provision of optimal patient care.
- Propose strategies to address microaggressions in a clinical setting.
- Describe the relationship between chronic pain and mental health conditions, such as depression and anxiety.
- Interpret the scores from validated instruments for comorbid chronic pain and depression, anxiety, and/or suicidal ideation.
- Develop an appropriate pharmacologic and/or non-pharmacologic treatment plan for patients experiencing comorbid chronic pain and depression/anxiety.
- Evaluate the risks of undertreated pain for patients with co-occurring opioid use disorder.
- Design a treatment plan to address co-occurring chronic pain and opioid use disorder.
- Choose treatments for acute pain in individuals receiving medication for opioid use disorder.
- Analyze evidence for psychedelics in the treatment of substance use disorders.
- Describe best practices for psychedelic implementation into substance use disorder treatment.
- Formulate a comprehensive treatment plan for patients undergoing psychedelic assisted therapy for a substance use disorder.
- Describe best practices of a street medicine team.
- Assess the role of the health care team members, including psychiatric pharmacists, in street medicine teams.
- Modify treatment regimens for individuals living unsheltered.
Target Audience
BCPPs desiring an evidence-based focus on emerging areas of practice and contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who learn best from didactic presentations, are auditory and visual learners, and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Faculty
View biographical information
Audrey Abelleira received her bachelor’s degree in biopsychology in 2014 and PharmD from Massachusetts College of Pharmacy in 2018. Following graduation she completed a PGY-1 pharmacy practice residency at Tufts Medicine’s MelroseWakefield Hospital in Melrose, MA and a PGY-2 psychiatric pharmacy residency at the Captain James A. Lovell Federal Health Care Center in North Chicago, IL. She is a board certified pharmacotherapy specialist and psychiatric pharmacist.
After completing residency Dr. Abelleira continued her clinical career as a mental health clinical pharmacist practitioner and clinical program manager, first at the VA Connecticut Healthcare System and then with the VA New England Clinical Resource Hub, providing care to veterans throughout New England. Her clinical practice was focused on integrating mental health and substance use disorders treatment into interdisciplinary chronic pain management teams. Her research interests included increasing access to medications for opioid use disorder, the intersection between chronic pain and psychiatric disorders, and optimizing virtual modalities for delivering interdisciplinary pain and mental health care.
Recently Dr. Abelleira has joined the neuropsychiatry field medical team at Bristol Myers Squibb as a medical science liaison focusing on novel therapies for severe mental illness.
Liz Frye, MD, MPH
Vice Chair, Board of Directors, Street Medicine Institute
Dr. Liz Frye is an internationally recognized expert in street psychiatry and has worked in the field for the past 15 years. She is the founder and CEO of a new street psychiatry consulting service, STREETconsults. With her medical and public health background, Dr. Frye develops strategies for addressing mental health and substance use disorders among unhoused people at a population health level. She is passionate about recognizing and addressing trauma as both a driver of and result from unsheltered homelessness. Her consulting work focuses on demystifying psychiatry and offering practical approaches for primary care clinicians to address complex co-occurring mental health and substance use disorders in the street medicine setting.
Dr. Frye previously founded and directed Atlanta’s first street medicine program and worked to integrate behavioral health into the AHN Center for Inclusion Health’s services, including street medicine, in Pittsburgh, Pennsylvania. Dr. Frye holds a medical degree from the University of North Carolina and a Master’s in Public Health from Emory University. She completed residency and a Community Psychiatry and Public Health Fellowship at Emory. In her free time, Dr. Frye serves as the Vice Chair for the Street Medicine Institute’s Board of Directors and has led the Institute’s annual International Street Medicine Symposia since 2017.
Dr. Wells graduated from Butler University and went on to complete a PGY-1 Pharmacy Practice Residency at the VA in Houston, TX and PGY-2 Psychiatric Pharmacy Residency with Purdue University and Wishard Health Services in Indianapolis, IN. Dr. Wells completed her MBA in 2019 from St. Mary's College of California and is board certified in Psychiatric Pharmacy (BCPP). She started her career as a Mental Health Clinical Pharmacy Practitioner at the VA in Columbia, SC working in outpatient mental health. Then moved on to serve as an Academic Detailer for the VISN 21/22 Academic Detailing Pilot Program. In 2015, she became an Education & Training Clinical Program Manager for PBM Academic Detailing Services (ADS) supporting education, training, and program implementation across VHA. In 2022, Dr. Wells accepted the position of Assistant Chief Consultant, PBM, ADS Education and Training and works out of the Seattle, WA area.
For more than 10 years, Dr. Wells has served as lead author for national educational materials on mental health disorders including ADHD, Insomnia Disorder, Opioid Use Disorder, Stimulant Use Disorder, and Treatment-resistant Depression. She currently serves as Co-Chair for the VHA Office of Mental Health and Suicide Prevention ADHD Workgroup and a member of the “Ask the Expert – ADHD” email consultation service for VHA.
Dr. Jeffrey Gold is a Psychiatric Clinical Pharmacy Practitioner and Psychopharmacologist with over 17 years of academic and clinical practice experience. His primary practice site is the Rocky Mountain Regional Veteran Affairs Medical Center in Colorado. He is a Senior Instructor for the University of Colorado at Denver Health Sciences Center School of Medicine Department of Psychiatry and School of Pharmacy. He earned his Doctor of Pharmacy degree at the University of Colorado Health Sciences Center and is a Board-Certified Psychiatric Pharmacotherapy Specialist.
Dr. Gold founded the Post-Graduate Year-Two Psychiatric Pharmacy Practice Residency at the Rocky Mountain Regional Veteran Affairs Medical Center and served as program director for ten years. He represents psychiatry as an advisory board member for the American Pharmacists Association (APhA) and is the past president of the former Colorado Psychiatric Pharmacy Association (CPPA). He was the first pharmacist in the state of Colorado to be granted a scope of practice to prescribe psychiatric medications and is licensed by the DEA to prescribe/manage controlled substances.
Dr. Gold is a direct care provider, consultant, and educator with an overall focus on providing clinical services to patients and instruction to healthcare trainees. He believes that psychotropic medications are started, adjusted, and stopped in the context of a relationship, and that is where the clinical work begins. Beyond this role, Dr. Gold serves the state of Colorado through active involvement in community-based program development and event planning around mental health and wellness, working in conjunction with various non-profit organizations, public school districts, and legal counsel. His areas of interest include trauma, psychotropic medication deprescribing, benzodiazepines, substance abuse, LGBTQ mental health, and the psychodynamic aspects of prescribing psychotropic medication.
Alexis Ritvo MD, MPH is a board-certified addiction psychiatrist. She is the Program Director for the Addiction Psychiatry Fellowship at the University of Colorado (CU) School of Medicine where she is an Assistant Professor of Psychiatry. She earned her Medical Degree and a Master’s in Public Health in Health Policy from Emory University in 2012. She completed her general psychiatry residency and addiction psychiatry fellowship at CU before joining faculty in 2017. Since then, she has been a supervising attending of general psychiatry residents in the CU Medicine Outpatient Psychiatry clinic where she directs a co-occurring disorder subspeciality clinic. Her growing interest in the safe prescribing and deprescribing of prescription benzodiazepines led her to co-found the Benzodiazepine Action Work Group with the Colorado Consortium for Prescription Drug Abuse in late 2020. In 2022, she became medical director for the national non-profit the Alliance for Benzodiazepines Best Practices. She is the current chair of the Education Committee for the American Association of Addiction Psychiatry. She has a passion for psychotherapy, teaching trainees, improving health systems, and advocacy.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (75%).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2024 Recertification Editorial Board
|
Marissa Cullen, PharmD, BCPP Clinical Pharmacist UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
 Beth DeJongh, PharmD, BCPS, BCPPDirector of Continuing Professional Development American Association of Psychiatric Pharmacists Lincoln, NE No Relevant Financial Relationships to Disclose |
|
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency VA Tennessee Valley Healthcare System Murfreesboro, TN Employment: Tennessee Valley VA Healthcare System, Clinical Pharmacy Specialist - Mental Health, Member of VA PBM Educational Advisory Committee which oversees Board Certification Study Groups |
Megan J. Ehret, PharmD, MS, BCPP |
|
Jordan Haygood, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry Medical University of South Carolina Charleston, SC No Relevant Financial Relationships to Disclose |
|
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Archana R. Jhawar, PharmD, BCPP Clinical Pharmacist Jesse Brown VAMC/ UIC College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
|
Linda D. Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, UGA Mental Health Seed Grants for MHFA and Virtual Dementia Tour, UGA College Pharmacy Ansel Fund |
|
Jessica L. Mulhollan, PharmD, BCPP Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor Louis Stokes Cleveland VA Medical Center Cleveland, OH No Relevant Financial Relationships to Disclose |
|
Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
|
Jake R. Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy/Indiana University Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
|
Sarah J. Popish, PharmD, BCPP VA PBM Academic Detailing Services, Program Manager Department of Veterans Affairs Sarasota, FL No Relevant Financial Relationships to Disclose |
|
Alisha Striedel, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
 Kara R. Wong, PharmD, BCPPRecertification Editorial Board Chair Clinical Pharmacist Practitioner, Mental Health Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.